Lanean...
Single dose oral rofecoxib for acute postoperative pain in adults
BACKGROUND: Editor's note: The anti‐inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long‐term use (greater than 18 months) could increase the risk of heart attack and stroke in a study of secondary prevention of adenoma recu...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Ltd
2009
|
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4171390/ https://ncbi.nlm.nih.gov/pubmed/19821329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD004604.pub3 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|